Phase 3 Trial: Maribavir Yields Post-Transplant Benefits

Maribavir may reduce mortality risk among patients with resistant or refractory post-transplant CMV infection following hematopoietic stem cell and solid organ transplant.

Related Keywords

Hebron ,Israel General ,Israel ,United States ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Maria Laura Fox ,Ishan Hirji ,Drug Administration ,Bristol Myers Squibb ,Glaxosmithkline ,Hebron Institute Of Oncology ,Takeda Development Center Americas ,European Society For Bone ,Novartis ,European Society ,Hebron Institute ,Sierra Oncology ,Transplantation Stem Cell ,Ransplantation Hematopoietic Stem Cell ,Hematopoietic Stem Cell Transplantation ,Stem Cell Transplantation ,Stem Cell Therapy ,Herapy Stem Cell ,Cytomegalovirus Cmv ,Cytomegalovirus ,Dmv ,Cytomegalovirus Infection ,Transplantation ,Transplant ,Transplantation Organ ,Organ Transplantation ,Transplant Center ,Refractory ,Acute Leukemia ,Europe ,European ,Graft ,Myelosup ,